Review of methods for measuring β-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium

Diabetes, Obesity and Metabolism

Volumn 20, Issue 1, 2018, Pages 14-24

  Hannon, Tamara S ^a   Kahn, Steven E ^b   Utzschneider, Kristina M ^b   Buchanan, Thomas A ^c   Nadeau, Kristen J ^d   Zeitler, Philip S ^d   Ehrmann, David A ^e   Arslanian, Silva A ^f   Caprio, Sonia ^g   Edelstein, Sharon L ^h   Savage, Peter J ⁱ   Mather, Kieren J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GEORGE WASHINGTON UNIVERSITY   (United States)

ⁱ NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

glucose metabolism; insulin resistance; insulin secretion; type 2 diabetes; cell

Indexed keywords

ARGININE; BIOLOGICAL MARKER; INSULIN;

CASE STUDY; FEASIBILITY STUDY; GLUCONEOGENESIS; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INSULIN RELEASE; INSULIN SENSITIVITY; LIMIT OF QUANTITATION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATHOGENESIS; RELIABILITY; REPRODUCIBILITY; REVIEW; STANDARDIZATION; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PATHOLOGY; POSTPRANDIAL STATE; SECRETION (PROCESS); TRENDS;

ARGININE; BIOMARKERS; DIABETES MELLITUS, TYPE 2; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MODELS, BIOLOGICAL; POSTPRANDIAL PERIOD; RESEARCH DESIGN;

EID: 85021301399     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13005     Document Type: Review

References (98)

1. Kahn SE. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med. 2000;108(suppl 6a):2S-8S.
2. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006;55:1430-1435.
3. Bacha F, Gungor N, Lee S, Arslanian SA. In vivo insulin sensitivity and secretion in obese youth: what are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes? Diabetes Care. 2009;32:100-105.
4. Weiss R, Caprio S, Trombetta M, Taksali SE, Tamborlane WV, Bonadonna R. Beta-cell function across the spectrum of glucose tolerance in obese youth. Diabetes. 2005;54:1735-1743.
5. Elder DA, Prigeon RL, Wadwa RP, Dolan LM, D'Alessio DA. Beta-cell function, insulin sensitivity, and glucose tolerance in obese diabetic and nondiabetic adolescents and young adults. J Clin Endocrinol Metab. 2006;91:185-191.
6. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
7. Bacha F, Gungor N, Lee S, Arslanian SA. Progressive deterioration of beta-cell function in obese youth with type 2 diabetes. Pediatr Diabetes. 2013;14:106-111.
8. Cali A, Dalla Man C, Cobelli C, et al. Primary defects in b-cell function further exacerbated by worsening of insulin resistance mark the development of impaired glucose tolerance in obese adolescents. Diabetes Care. 2009;32:456-461.
9. Shankar SS, Vella A, Raymond RH, et al. Standardized mixed-meal tolerance and arginine stimulation tests provide reproducible and complementary measures of beta-cell function: results from the foundation for the National Institutes of Health biomarkers consortium investigative series. Diabetes Care. 2016;39:1602-1613.
10. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993;42:1663-1672.
11. Kahn SE, Carr DB, Faulenbach MV, Utzschneider KM. An examination of beta-cell function measures and their potential use for estimating beta-cell mass. Diabetes Obes Metab. 2008;10(suppl 4):63-76.
12. Sjaarda L, Lee S, Tfayli H, Bacha F, Bertolet M, Arslanian S. Measuring beta-cell function relative to insulin sensitivity in youth: does the hyperglycemic clamp suffice? Diabetes Care. 2013;36:1607-1612.
13. Bacha F, Gungor N, Arslanian SA. Measures of beta-cell function during the oral glucose tolerance test, liquid mixed-meal test, and hyperglycemic clamp test. J Pediatr. 2008;152:618-621.
14. Bergman RN, Ader M, Heucking K, Van Citters G. Accurate assessment of beta-cell function. The hyperbolic correction. Diabetes. 2002;51:S212-S220.
15. Wallace TM, Matthews DR. Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. Diabet Med. 2002;19:465-469.
16. Davis SN, Piatti PM, Monti L, et al. A comparison of four methods for assessing in vivo beta-cell function in normal, obese and non-insulin-dependent diabetic man. Diabetes Res. 1992;19:107-117.
17. Nadeau KJ, Mather KM, Arslanian SA, et al. Restoring Insulin Secretion (RISE): design of studies of beta-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care. 2014;37:780-788.
18. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens. 1998;16:895-906.
19. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462-1470.
20. Xiang AH, Watanabe RM, Buchanan TA. HOMA and Matsuda indices of insulin sensitivity: poor correlation with minimal model-based estimates of insulin sensitivity in longitudinal settings. Diabetologia. 2014;57:334-338.
21. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
22. Elahi D. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care. 1996;19:278-286.
23. Toffolo G, Bergman RN, Finegood DT, Bowden CR, Cobelli C. Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog. Diabetes. 1980;29:979-990.
24. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981;68:1456-1467.
25. Pfeifer MA, Halter JB, Beard JC, Porte D Jr. Differential effects of tolbutamide on first and second phase insulin secretion in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1981;53:1256-1262.
26. Prigeon RL, Roder ME, Porte D Jr, Kahn SE. The effect of insulin dose on the measurement of insulin sensitivity by the minimal model technique. Evidence for saturable insulin transport in humans. J Clin Invest. 1996;97:501-507.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
28. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402-2410.
29. Mather KJ, Hunt AE, Steinberg HO, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab. 2001;86:5457-5464.
30. Giannini C, Weiss R, Cali A, et al. Evidence for early defects in insulin sensitivity and secretion before the onset of glucose dysregulation in obese youths: a longitudinal study. Diabetes. 2012;61:606-614.
31. Tura A, Grassi A, Winhofer Y, et al. Progression to type 2 diabetes in women with former gestational diabetes: time trajectories of metabolic parameters. PLoS ONE. 2012;7:e50419.
32. O'Meara NM, Sturis J, Van Cauter E, Polonsky KS. Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest. 1993;92:262-271.
33. Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988;81:442-448.
34. Ahren B, Holst JJ, Mari A. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care. 2003;26:2860-2864.
35. Dalla Man C, Micheletto F, Sathananthan M, Vella A, Cobelli C. Model-based quantification of glucagon-like peptide-1-induced potentiation of insulin secretion in response to a mixed meal challenge. Diabetes Technol Ther. 2016;18:39-46.
36. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest. 1984;74:1318-1328.
37. Pfeifer MA, Halter JB, Porte D Jr. Insulin secretion in diabetes. Am J Med. 1981;70:579-588.
38. Ferrannini E, Pilo A. Pattern of insulin delivery after intravenous glucose injection in man and its relation to plasma glucose disappearance. J Clin Invest. 1979;64:243-254.
39. Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab. 1976;42:222-229.
40. Ward WK, Beard JC, Halter JB, Porte D Jr. Pathophysiology of insulin secretion in diabetes mellitus. Adv Exp Med Biol. 1985;189:137-158.
41. Kanat M, Norton L, Winnier D, Jenkinson C, DeFronzo RA, Abdul-Ghani MA. Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose. Acta Diabetol. 2011;48:209-217.
42. O'Connor MD, Landahl H, Grodsky GM. Comparison of storage- and signal-limited models of pancreatic insulin secretion. Am J Physiol. 1980;238:R378-R389.
43. Nesher R, Cerasi E. Modeling phasic insulin release: immediate and time-dependent effects of glucose. Diabetes. 2002;51(suppl 1):S53-S59.
44. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110.
45. Hannon TS, Kirkman MS, Patel YR, Considine RV, Mather KJ. Profound defects in beta-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the early diabetes prevention program (EDIP). Diabetes Metab Res Rev. 2014;30(8):767-776.
46. Pennartz C, Schenker N, Menge BA, Schmidt WE, Nauck MA, Meier JJ. Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes. Diabetes Care. 2011;34:2048-2053.
47. Martinussen C, Bojsen-Moller KN, Dirksen C, et al. Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. Am J Physiol Endocrinol Metab. 2015;308:E535-E544.
48. Nijpels G, Boorsma W, Dekker JM, et al. Absence of an acute insulin response predicts onset of type 2 diabetes in a Caucasian population with impaired glucose tolerance. J Clin Endocrinol Metab. 2008;93:2633-2638.
49. Xiang AH, Kawakubo M, Trigo E, Kjos SL, Buchanan TA. Declining beta-cell compensation for insulin resistance in Hispanic women with recent gestational diabetes mellitus: association with changes in weight, adiponectin, and C-reactive protein. Diabetes Care. 2010;33:396-401.
50. Xiang AH, Kjos SL, Takayanagi M, Trigo E, Buchanan TA. Detailed physiological characterization of the development of type 2 diabetes in Hispanic women with prior gestational diabetes mellitus. Diabetes. 2010;59:2625-2630.
51. Bonadonna RC, Stumvoll M, Fritsche A, et al. Altered homeostatic adaptation of first- and second-phase beta-cell secretion in the offspring of patients with type 2 diabetes: studies with a minimal model to assess beta-cell function. Diabetes. 2003;52:470-480.
52. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;96:520-527.
53. Buchanan TA, Xiang A, Kjos SL, et al. Gestational diabetes: antepartum characteristics that predict postpartum glucose intolerance and type 2 diabetes in Latino women. Diabetes. 1998;47:1302-1310.
54. Junqueira Vasques AC, Pareja JC, de Oliveira Mda S, et al. Beta-Cell function improvements in grade I/II obese subjects with type 2 diabetes 1 month after biliopancreatic diversion: results from modeling analyses of oral glucose tolerance tests and hyperglycemic clamp studies. Diabetes Care. 2013;36:4117-4124.
55. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55:517-522.
56. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002;51:2796-2803.
57. Byrne MM, Sturis J, Polonsky KS. Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol. 1995;268:E21-E27.
58. Ehrmann DA, Breda E, Cavaghan MK, et al. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia. 2002;45:509-517.
59. Toffolo G, Breda E, Cavaghan MK, Ehrmann DA, Polonsky KS, Cobelli C. Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab. 2001;280:E2-E10.
60. Chen M, Porte D Jr. The effect of rate and dose of glucose infusion on the acute insulin response in man. J Clin Endocrinol Metab. 1976;42:1168-1175.
61. Shankar SS, Shankar RR, Mixson LA, et al. Linearity of beta-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series. Am J Physiol Endocrinol Metab. 2016;310:E865-E873.
62. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997;100:530-537.
63. Hollander PM, Asplin CM, Palmer JP. Glucose modulation of insulin and glucagon secretion in nondiabetic and diabetic man. Diabetes. 1982;31:489-495.
64. Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D Jr. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care. 1984;7:491-502.
65. van Haeften TW, Voetberg GA, Gerich JE, van der Veen EA. Dose-response characteristics for arginine-stimulated insulin secretion in man and influence of hyperglycemia. J Clin Endocrinol Metab. 1989;69:1059-1064.
66. Robertson RP, Raymond RH, Lee DS, et al; Beta Cell Project Team of the Foundation for the NIH Biomarkers Consortium. Arginine is preferred to glucagon for stimulation testing of beta-cell function. Am J Physiol Endocrinol Metab. 2014;307:E720-E727.
67. Rickels MR, Mueller R, Teff KL, Naji A. {beta}-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. J Clin Endocrinol Metab. 2010;95:1238-1246.
68. Robertson RP, Bogachus LD, Oseid E, et al. Assessment of beta-cell mass and alpha- and beta-cell survival and function by arginine stimulation in human autologous islet recipients. Diabetes. 2015;64:565-572.
69. Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med. 2008;25:152-156.
70. Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014;2:464-473.
71. Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med. 1994;11:286-292.
72. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE; American Diabetes Association GENNID Study Group. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes. 2002;51:2170-2178.
73. Sjaarda LG, Bacha F, Lee S, Tfayli H, Andreatta E, Arslanian S. Oral disposition index in obese youth from normal to prediabetes to diabetes: relationship to clamp disposition index. J Pediatr. 2012;161:51-57.
74. Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring). 2008;16:1901-1907.
75. Utzschneider KM, Prigeon RL, Faulenbach MV, et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care. 2009;32:335-341.
76. Burns SF, Bacha F, Lee SJ, Tfayli H, Gungor N, Arslanian SA. Declining beta-cell function relative to insulin sensitivity with escalating OGTT 2-h glucose concentrations in the nondiabetic through the diabetic range in overweight youth. Diabetes Care. 2011;34:2033-2040.
77. Kahn SE, Lachin JM, Zinman B, et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes. 2011;60:1552-1560.
78. Michaliszyn SF, Mari A, Lee S, et al. Beta-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes. 2014;63:3846-3855.
79. Cobelli C, Dalla Man C, Toffolo G, Basu R, Vella A, Rizza R. The oral minimal model method. Diabetes. 2014;63:1203-1213.
80. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab. 2002;283:E1159-E1166.
81. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes. 2001;50:150-158.
82. Libman IM, Barinas-Mitchell E, Bartucci A, Robertson R, Arslanian S. Reproducibility of the oral glucose tolerance test in overweight children. J Clin Endocrinol Metab. 2008;93:4231-4237.
83. Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes. 1999;48:1779-1786.
84. Utzschneider KM, Prigeon RL, Tong J, et al. Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies. Diabetologia. 2007;50:2516-2525.
85. Jimenez A, Mari A, Casamitjana R, Lacy A, Ferrannini E, Vidal J. GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes. Diabetes. 2014;63:3372-3377.
86. Rijkelijkhuizen JM, McQuarrie K, Girman CJ, et al. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses. Metabolism. 2010;59:502-511.
87. Rijkelijkhuizen JM, Girman CJ, Mari A, et al. Classical and model-based estimates of beta-cell function during a mixed meal vs. an OGTT in a population-based cohort. Diabetes Res Clin Pract. 2009;83:280-288.
88. Bacha F, Gungor N, Lee S, de Las Heras J, Arslanian S. Indices of insulin secretion during a liquid mixed-meal test in obese youth with diabetes. J Pediatr. 2013;162(5):924-929.
89. Bock G, Dalla Man C, Campioni M, et al. Effects of nonglucose nutrients on insulin secretion and action in people with pre-diabetes. Diabetes. 2007;56:1113-1119.
90. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al;. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care. 2008;31:1966-1971.
91. Bacha F, Lee S, Gungor N, Arslanian SA. From pre-diabetes to type 2 diabetes in obese youth: pathophysiological characteristics along the spectrum of glucose dysregulation. Diabetes Care. 2010;33:2225-2231.
92. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY. Proinsulin as a marker for the development of NIDDM in Japanese-American men. Diabetes. 1995;44:173-179.
93. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia. 1987;30:698-702.
94. Saad MF, Kahn SE, Nelson RG, et al. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1990;70:1247-1253.
95. Hill NR, Levy JC, Matthews DR. Expansion of the homeostasis model assessment of beta-cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2. Diabetes Care. 2013;36:2324-2330.
96. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191-2192.
97. Gungor N, Saad R, Janosky J, Arslanian S. Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J Pediatr. 2004;144:47-55.
98. Derosa G, Carbone A, Franzetti I, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, beta-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract. 2012;98:51-60.